Development

自上次审查以来，癌症研究所已经招募了24名新成员：7名翻译，8名 基础科学家和9名临床医生表7.5.1显示了迄今为止的征聘情况。虽然NYUCI机构基金 用于支持这些新兵的费用，CCSG资金用于资助 实验室的许多这些新兵，并资助新的核心，没有这些招聘将不会 已经成为可能（例如基因组学设施和siRNA核心）。如第6.0节所述，NYUCI招募 在上一个供资期间分三个阶段进行。第一阶段的重点是招募关键人员， 这将是对现有社区的补充。因此，招聘博士。 Bhardwaj和奥尼尔扩展了免疫学的现有优势，包括免疫疗法以及 将黑色素瘤添加到我们基于CCSG疾病的计划中，该计划已经包括泌尿生殖系统和乳腺癌 癌病理学系主任，大卫罗斯，医学博士，博士，和联合项目负责人的 免疫学计划借给癌症研究所的空间，用于早期招募Bhardwaj博士，Dynlacht 还有奥尼尔。今年，Bhardwaj博士和Dynlacht博士搬进了癌症研究中心， 博士奥尼尔到疫苗设施。 第二阶段的重点是增加临床项目的深度，并对招募人员进行具体投资 这将扩大临床服务和研究能力。临床癌症中心于2004年7月开业， 以及招募基于疾病的、程序化排列的临床医生（例如Novik，Axelrod，Tiersten， 钱德拉，斯金纳和其他人）之前，它的开放提供了一个多学科的临床环境， 从一开始的研究和关怀。目前，NYUCI有12个疾病管理小组。最后以 2006年5月，Smilow研究中心开幕，癌症研究中心的三个研究楼层 学校开学了，最新的学生也来到了学校（Dasgupta、Yamasaki、Cho、Krogsgaard、Trombetta）。 发展基金被指定用于招聘临床研究副主任，以建立 临床研究企业和促进跨研究实体的合作，以将实验室发现转化为 诊所，招募一名分子流行病学家，在各种项目中进行研究，并建立一个 合作和互动的流行病学和预防方案。这些优先事项是根据 《战略计划》的各项举措和EAB的建议。2005年，医学博士威廉卡罗尔被 被任命为肿瘤研究所副所长，负责企业的临床研究。是的， 然而，在招募分子流行病学家失败，并在2005年，罗伊博士海岸，助理 流行病学和预防主任在日本担任了一个职位，并努力招聘人员填补这一职位 成了我们的首要任务2006年初，一位候选人正在进行最后谈判，但决定留在他的职位上 机构。CI正在积极招聘这两个职位，并正在与其中一个职位进行初步谈判。 副主任职位的最终候选人;我们的计划是通过实地考察来填补这个职位。

Since the previous review, there have been 24 recruits to the Cancer Institute: seven translational, eight basic scientists, and nine clinical. Table 7.5.1 shows recruitments to date. While NYUCI institutional funds were used to support the expense of these recruits CCSG funds were used to fund pilot projects in the laboratories of many of these recruits, and to fund new cores without which these recruitments would not have been possible (e.g. Genomics Facility and siRNA core). As mentioned in Section 6.0 NYUCI recruitment took place in three phases during the last funding period. The first phase focused on key recruits with significant cancer focus that would complement the existing community. Thus the recruitment of Drs. Bhardwaj and O'Neill extended existing excellence in immunology to include immunotherapy as well as adding melanoma to our CCSG disease based programs that already included Genitourinary and Breast Cancer. The Chair of the Department of Pathology, David Roth, MD, PhD, and Co-Program Leader of the Immunology Program loaned the Cancer Institute space for the early recruitments of Drs. Bhardwaj, Dynlacht and O'Neill. This year, Drs. Bhardwaj and Dynlacht have since moved into the Cancer Research Center and Dr. O'Neill to the Vaccine Facility. The second phase focused on increasing depth in the clinical program with specific investments in recruits that would expand clinical services and research capabilities. The Clinical Cancer Center opened July 2004, and recruitment for disease based, programmatically aligned clinicians (e.g. Novik, Axelrod, Tiersten, Chandra, Skinner and others) prior to its opening provided for an environment of multi-disciplinary clinical research and care from its inception. Currently the NYUCI has 12 Disease Management Groups. Finally, with the opening of the Smilow Research Center May 2006, the three research floors of the Cancer Research Center opened and the newest recruits arrived on campus (Dasgupta, Yamasaki, Cho, Krogsgaard, Trombetta). Developmental Funds were earmarked to recruit a Deputy Director for Clinical Research to build the clinical research enterprise and foster collaborations across research entities to translate laboratory findings in the clinic, to recruit a molecular epidemiologist to bridge research within various programs, and build a collaborative and interactive Epidemiology and Prevention Program. These priorities were based upon the initiatives of the Strategic Plan and the recommendations of the EAB. In 2005, William Carroll, MD was named the Deputy Director for the Cancer Institute, responsible for the clinical research enterprise. We were, however, unsuccessful in recruiting a Molecular Epidemiologist, and in 2005, Dr. Roy Shore, the Associate Director for Epidemiology and Prevention took a position in Japan, and recruitment efforts to fill this position became our highest priority. In early 2006, a candidate was in final negotiations, yet decided to stay at his institution. The CI is actively recruiting for both positions and is in preliminary negotiations with one of the final candidates for the Associate Director position; our plan is to have this position filled by the Site Visit.